Jason Rhodes Sells 274,297 Shares of Dyne Therapeutics (NASDAQ:DYN) Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Jason Rhodes sold 274,297 shares of Dyne Therapeutics stock in a transaction that occurred on Tuesday, April 21st. The stock was sold at an average price of $19.52, for a total value of $5,354,277.44. Following the transaction, the director directly owned 13,148 shares in the company, valued at approximately $256,648.96. This trade represents a 95.43% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dyne Therapeutics Price Performance

DYN stock opened at $18.90 on Friday. The company has a market capitalization of $3.12 billion, a P/E ratio of -5.34 and a beta of 1.29. Dyne Therapeutics, Inc. has a twelve month low of $8.06 and a twelve month high of $25.00. The business has a 50 day simple moving average of $17.64 and a 200-day simple moving average of $18.37. The company has a current ratio of 22.25, a quick ratio of 22.25 and a debt-to-equity ratio of 0.15.

Dyne Therapeutics (NASDAQ:DYN) last announced its earnings results on Monday, March 2nd. The company reported ($0.76) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.02). As a group, equities analysts anticipate that Dyne Therapeutics, Inc. will post -2.94 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Dyne Therapeutics in a research note on Monday. Chardan Capital reiterated a “buy” rating and set a $38.00 target price on shares of Dyne Therapeutics in a research note on Monday, March 9th. Jefferies Financial Group restated a “buy” rating on shares of Dyne Therapeutics in a research report on Monday, March 9th. Morgan Stanley reduced their price objective on Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating for the company in a research note on Monday, March 2nd. Finally, Wall Street Zen cut Dyne Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, December 28th. Three investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Dyne Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $35.14.

Hedge Funds Weigh In On Dyne Therapeutics

A number of large investors have recently bought and sold shares of DYN. AQR Capital Management LLC acquired a new stake in shares of Dyne Therapeutics in the 1st quarter worth $246,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Dyne Therapeutics by 5.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,466 shares of the company’s stock worth $597,000 after acquiring an additional 2,886 shares during the period. Goldman Sachs Group Inc. raised its holdings in Dyne Therapeutics by 58.2% during the first quarter. Goldman Sachs Group Inc. now owns 994,886 shares of the company’s stock worth $10,407,000 after purchasing an additional 366,183 shares in the last quarter. Caxton Associates LLP purchased a new position in Dyne Therapeutics during the first quarter worth about $157,000. Finally, Creative Planning raised its holdings in Dyne Therapeutics by 23.8% during the second quarter. Creative Planning now owns 14,541 shares of the company’s stock worth $138,000 after purchasing an additional 2,797 shares in the last quarter. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.